<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01326403</url>
  </required_header>
  <id_info>
    <org_study_id>TASMC-11-ES-0129-CTIL</org_study_id>
    <nct_id>NCT01326403</nct_id>
  </id_info>
  <brief_title>Tranexamic Acid in Hip Fracture Patients</brief_title>
  <official_title>Tranexamic Acid in Hip Fracture Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Michal Roll PhD,MBA</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Tel-Aviv Sourasky Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Tel-Aviv Sourasky Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized controlled trial comparing the use of tranexamic acid to placebo in
      patients admitted to hospital with a hip fracture.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. transfusion of allogeneic RBC's is not free of adverse events and has been associated
           with an increased risk of postoperative infection

        2. Tranexamic acid in trauma patients has been shown to reduce 30-day mortality. Hospital
           trauma protocol includes tranexamic acid in patients with major bleeding.

        3. Tranexamic acid in orthopedic elective joint reconstruction surgery has been shown to
           substantially decrease bleeding in knee and hip arthroplasty.

        4. in hip fracture surgery, transexamic acid reduces erythrocyte transfusion rate but may
           promote a hypercoagulable state.

        5. Tranexamic acid is an antifibrinolytic drug that inhibits plasminogen from turning into
           plasmin thereby inhibiting clot breakdown.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>June 2012</start_date>
  <completion_date type="Anticipated">June 2013</completion_date>
  <primary_completion_date type="Anticipated">June 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total amount of blood loss per patient from admission to day 5 post-op</measure>
    <time_frame>5 DAYS</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of packed cell transfusion per patient.</measure>
    <time_frame>5 DAYS</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Initial functional outcome and feeling of well-being.</measure>
    <time_frame>5 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>thromboembolic events</measure>
    <time_frame>5 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>post-operative bacterial infection</measure>
    <time_frame>5 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>30 day mortality rate</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Closed Fracture of Hip</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive IV Tranexamic acid 1 gram upon diagnosis and consent in the emergency room. A second 1 gram in a slow drip during the next 8 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GROUP B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive IV Tranexamic acid 1 gram five minutes before skin incision and a second 1 gram in a slow drip during the next 8 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GROUP C</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>A control group will only receive placebo in the emergency room and in the OR.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tranexamic acid</intervention_name>
    <description>GROUP A - receive IV Tranexamic acid 1 gram upon diagnosis and consent in the emergency room. A second 1 gram in a slow drip during the next 8 hours.
GROUP B - IV Tranexamic acid 1 gram five minutes before skin incision and a second 1 gram in a slow drip during the next 8 hours.
Group C - A control group will only receive placebo in the emergency room and in the OR.</description>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>GROUP B</arm_group_label>
    <arm_group_label>GROUP C</arm_group_label>
    <other_name>placebo group</other_name>
    <other_name>post injury group</other_name>
    <other_name>preoperative group</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients admitted to the emergency room with proximal hip fractures (31A-31B according
             to the Muller AO classification of fractures - long bones).

          -  Patients mentally capable of giving informed consent.

        Exclusion Criteria:

          1. Vascular events within the last 2 months such as CVA, TIA, ACS, MI, DVT or arterial
             thrombosis.

          2. Patients receiving anticoagulation therapy with Coumadin or Plavix.

          3. Pregnancy and breastfeeding females.

          4. Previous arterial or venous thrombosis

          5. History of seizures.

          6. Creatinine &gt;2.

          7. Oestroprogestive therapy.

          8. Multiple fractures.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>ELI SHTEINBERG, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tel-Aviv Sourasky Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sourasky Medical Center</name>
      <address>
        <city>Tel Aviv</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>ELI STEINBERG, MD</last_name>
      <phone>0524266346</phone>
      <email>STEINBERGE@TASMC.HEALTH.GOV.IL</email>
    </contact>
    <contact_backup>
      <last_name>AMIR SHLAIFER, MD</last_name>
      <phone>0527360803</phone>
      <email>SHLAIFER.MD@GMAIL.COM</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>June 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 21, 2011</study_first_submitted>
  <study_first_submitted_qc>March 29, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 30, 2011</study_first_posted>
  <last_update_submitted>June 6, 2012</last_update_submitted>
  <last_update_submitted_qc>June 6, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 7, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Tel-Aviv Sourasky Medical Center</investigator_affiliation>
    <investigator_full_name>Michal Roll PhD,MBA</investigator_full_name>
    <investigator_title>division of research and development TASMC</investigator_title>
  </responsible_party>
  <keyword>proximal</keyword>
  <keyword>hip</keyword>
  <keyword>fractures</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fractures, Bone</mesh_term>
    <mesh_term>Hip Fractures</mesh_term>
    <mesh_term>Fractures, Closed</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tranexamic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

